文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

CRISPR编辑T细胞治疗难治性非小细胞肺癌的安全性与可行性

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
PubMed 文献 · Nat Med · 2020-04-27

该首次人体I期试验评估CRISPR-Cas9 PD-1编辑T细胞治疗晚期非小细胞肺癌的安全性与可行性。22例入组,17例制备成功,12例接受输注;所有治疗相关不良事件为1/2级,中位无进展生存7.7周,中位总生存42.6周,脱靶突变频率中位0.05%。

要点

  • CRISPR-Cas9 PD-1编辑T细胞治疗晚期NSCLC总体安全可行。
  • 治疗相关不良事件均为1/2级,未报告更高级别事件。
  • 中位PFS 7.7周,中位OS 42.6周,疗效仍需优化。

核心结论

  • CRISPR-Cas9基因编辑T细胞的临床应用总体安全可行,未来试验应采用更优编辑方法提高疗效。

研究设计与样本

  • 首次人体I期临床试验(NCT02793856),纳入晚期非小细胞肺癌患者。
  • 主要终点为安全性和可行性,次要终点为疗效,探索性目标包括追踪编辑T细胞。

主要发现

  • 22例患者入组,17例制备出足够编辑T细胞,12例接受治疗。
  • 所有治疗相关不良事件为1/2级。
  • 输注后外周血可检测到编辑T细胞。
  • 中位无进展生存7.7周(95%CI 6.9-8.5周),中位总生存42.6周(95%CI 10.3-74.9周)。
  • 18个候选位点二代测序显示脱靶突变频率中位0.05%(范围0-0.25%)。

临床怎么用

  • 支持CRISPR-Cas9 PD-1编辑T细胞在晚期NSCLC中的后续临床开发。
  • 治疗相关毒性以1/2级为主,需持续监测脱靶事件。

局限性

  • 样本量小,仅12例接受治疗,疗效结论受限。
  • 疗效有限,需采用更优基因编辑策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 editing of immune checkpoint genes could improve the efficacy of T cell therapy, but the first necessary undertaking is to understand the safety and feasibility. Here, we report results from a first-in-human phase I clinical trial of CRISPR-Cas9 PD-1-edited T cells in patients with advanced non-small-cell lung cancer (ClinicalTrials.gov NCT02793856). Primary endpoints were safety and feasibility, and the secondary endpoint was efficacy. The exploratory objectives included tracking of edited T cells. All prespecified endpoints were met. PD-1-edited T cells were manufactured ex vivo by cotransfection using electroporation of Cas9 and single guide RNA plasmids. A total of 22 patients were enrolled; 17 had sufficient edited T cells for infusion, and 12 were able to receive treatment. All treatment-related adverse events were grade 1/2. Edited T cells were detectable in peripheral blood after infusion. The median progression-free survival was 7.7 weeks (95% confidence interval, 6.9 to 8.5 weeks) and median overall survival was 42.6 weeks (95% confidence interval, 10.3-74.9 weeks). The median mutation frequency of off-target events was 0.05% (range, 0-0.25%) at 18 candidate sites by next generation sequencing. We conclude that clinical application of CRISPR-Cas9 gene-edited T cells is generally safe and feasible. Future trials should use superior gene editing approaches to improve therapeutic efficacy.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Lu Y, Xue J, Deng T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020. PMID: 32341578. doi:10.1038/s41591-020-0840-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。